Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

taVNS for Persistent Symptoms From Lyme Disease

NCT: NCT05776251 · RECRUITING

NCT IDNCT05776251
StatusRECRUITING
Start Date2023-05-08
Completion2026-12

Brief Summary

This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to reduce the burden of multisystem symptoms in patients with PTLS. This study seeks to address an important goal: to assess the safety, feasibility, and tolerability of a new non-invasive, non-pharmacologic treatment for patients with symptoms that persist despite prior antibiotic treatment for Lyme disease.

Frequently Asked Questions

What is taVNS for Persistent Symptoms From Lyme Disease?

taVNS for Persistent Symptoms From Lyme Disease is a clinical trial registered under NCT05776251. Current status: RECRUITING.

What is the status of NCT05776251?

The current status of NCT05776251 (taVNS for Persistent Symptoms From Lyme Disease) is: RECRUITING.

When did taVNS for Persistent Symptoms From Lyme Disease start?

taVNS for Persistent Symptoms From Lyme Disease started on 2023-05-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.